Mr. Alexander Dobranowski reports

MCI ONEHEALTH ANNOUNCES INVESTMENT IN AND COMMERCIAL SUPPORT FOR ACORN BIOLABS, INC., PAVING NEW FRONTIER IN PRECISION MEDICINE

MCI Onehealth Technologies Inc. has made an investment of $250,000 with Acorn Biolabs Inc., a Toronto-based biotechnology company. Acorn Biolabs is revolutionizing regenerative and precision medicine through its easy, affordable and non-invasive stem cell collection, analysis and cryopreservation service, which is up to 80 per cent more cost-effective than the current exclusionary industry average.

This investment allows MCI Onehealth to accelerate execution of its precision health and technology road map while also supporting the company's long-term vision of building a data-driven, technology-enabled health service platform. As a leader in primary care, MCI Onehealth's collaboration with Acorn Biolabs further expands MCI's business from a bricks and mortar clinic network toward a data-driven, technology-enabled health service platform.

"MCI Onehealth is unlocking an exciting new phase of precision medicine that will play an integral role in the future of health care," said Alexander Dobranowski, MD, chief executive officer of MCI Onehealth. "By expanding our personalized and preventative health care services through innovations like Acorn's industry-leading stem cell harvesting and storage, our ongoing mission to improve patient outcomes and save lives is made significantly stronger."

In addition to the capital investment, MCI will be providing commercial support to Acorn's innovative solution for live cell collection. Select MCI clinics will begin offering Acorn services, including non-invasive hair-follicle-based stem cell collection and storage, as well as live cell and genetic analytics, with availability throughout the MCI network by the end of the year.

By freezing a patient's healthy cells and allowing them to be leveraged when needed, Acorn Biolabs aims to give its patients the ability to live longer, healthier lives through regenerative medicine.

"This is just the beginning of our story with MCI Onehealth as both a capital investor in our stem cell technology and by offering it to an entirely new audience of Canadians," said Dr. Drew Taylor, co-founder and chief executive officer at Acorn Biolabs. "This is a very exciting opportunity which integrates our technology into MCI's large and well-operated network of medical clinics and allows us to have a role in advancing precision health as a whole."

This strategic relationship will allow MCI Onehealth to provide commercial support to Acorn Biolabs by offering its innovative and industry-leading affordable stem cell collection and storage to its 850,000-plus yearly patients while also expanding its selection of service offerings. MCI Onehealth is committed to growth as a means of empowering physicians and putting patients' health first.

As a leader in primary care, MCI Onehealth's partnership with Acorn Biolabs further expands its business from a bricks and mortar clinic network toward a data-driven, modernized, technology-enabled health service platform.

About MCI Onehealth Technologies Inc.

MCI Onehealth is a health care technology company focused on empowering patients and doctors with advanced technologies to increase access, improve quality and reduce health care costs. As part of the health care community for over 30 years, MCI Onehealth operates one of Canada's leading primary care networks with 25 clinics, serves over 850,000 patients annually and had over 200,000 telehealth visits last year. MCI Onehealth additionally offers an expanding suite of occupational health service offerings that support a growing list of over 250 corporate customers. Led by a proven management team of doctors and experienced executives, MCI Onehealth remains focused on executing a strategy centred around acquiring technology and health services that complement the company's current road map.

We seek Safe Harbor.